Hair Growth Serum Claims in the UK: A Screening Guide for Private-Label Brands

A Hair Growth Serum can create UK claim-classification risk before a private-label brand has placed its first packaging order. The critical control is not the product name alone: it is the exact wording used on the label, product-detail page, marketplace listing, paid advertisement and other UK-facing marketing material. UK advertising guidance indicates that claims to prevent or cure baldness, hair loss or male-pattern baldness are likely to be medicinal claims. By contrast, claims about reducing hair loss, strengthening hair, or promoting existing hair growth may be non-medicinal when robust evidence supports them. [1]

For procurement and brand teams, the practical decision is therefore to classify each proposed statement before artwork is approved: escalate wording that presents prevention or cure; hold for substantiation review wording that may be non-medicinal but depends on robust evidence; or approve only after the documented review is complete. This guide provides a pre-approval screen, not a legal determination, efficacy assessment or complete UK cosmetics compliance review.

1. Scope: What This UK Claim-Screening Guide Covers

This guide applies to private-label hair growth serums and related hair-care products marketed in the United Kingdom with wording about baldness, hair loss, male-pattern baldness, hair strengthening or hair growth. It is intended for packaging copy, product pages, online listings, paid advertising and brand marketing materials.

The guide addresses one narrow but commercially important question: whether proposed wording should move through normal evidence review or be escalated because it is likely to be treated as a medicinal claim under the supplied UK advertising guidance. It does not determine whether a particular formula works, whether an ingredient is suitable, or whether a finished product meets all applicable product, labelling, safety or market-access obligations.

Do not transfer this screen to the EU, United States, China, ASEAN, GCC, Canada, Australia or another market. Claim interpretation is jurisdiction-specific, and a separate market review is needed for each launch territory.

2. Why Claim Wording Must Be Locked Before Artwork and Marketing Approval

A private-label project often distributes the same commercial idea across a carton, bottle label, supplier artwork file, website, marketplace listing and advertising creative. Small wording changes can materially alter the claim presented to the consumer. A claim screen should therefore occur before label printing, listing activation or campaign release—not after stock has been produced or media has been booked.

The supplied UK guidance draws a meaningful distinction between claims that a product can prevent or cure baldness, hair loss or male-pattern baldness, and claims that a product could slow down or reduce hair loss or promote or strengthen existing hair growth. The former are likely to be medicinal claims; the latter may be non-medicinal only where robust evidence exists. [1]

For a procurement manager, this distinction supports a practical release gate. Artwork should not be treated as final merely because a supplier has prepared a print-ready file or a marketing team has approved its visual design. The exact UK-facing claim language, its intended medium and the status of supporting material should travel together in the approval record.

3. UK Screening Categories for Baldness, Hair Loss and Hair-Growth Wording

The matrix below is a wording screen, not a substitute for review of the complete advertisement or product presentation. Context, qualifiers, imagery and the combined impression of a claim can matter. Its purpose is to identify language that should not proceed through an ordinary packaging approval route.

Table 1. UK Hair Growth Serum Claim-Screening Matrix

Proposed claim wording category	Examples of wording covered by supplied guidance	Likely claim-screening outcome	Required next action before approval
Prevention or cure claim	“Prevents baldness”; “cures hair loss”; “cures male-pattern baldness”	Likely medicinal claim. [1]	Do not approve through the ordinary private-label copy route. Escalate for specialist medicinal-claim assessment before release.
Hair-loss reduction wording	“Reduces hair loss” or wording that a product could slow down hair loss	May be non-medicinal if robust evidence exists. [1]	Hold pending a documented robustness review of the supporting material for the final wording and use context.
Hair-strengthening wording	“Strengthens hair”	May be non-medicinal if robust evidence exists. [1]	Confirm robust supporting material before approval; do not assume that a formula description alone substantiates the statement.
Existing-hair-growth wording	“Promotes existing hair growth”	May be non-medicinal if robust evidence exists. [1]	Require substantiation review before release and check that surrounding copy does not add prevention or cure language.

The examples in Table 1 are screening anchors. They should not be expanded into broader efficacy promises without a fresh review. In particular, changing a potentially non-medicinal phrase by adding “prevents,” “cures,” “baldness” or “male-pattern baldness” may change the classification risk indicated by the guidance. [1]

4. The Robust-Substantiation Checkpoint

Lower-risk wording is not automatically approved wording. The supplied guidance qualifies potentially non-medicinal statements about slowing down or reducing hair loss, promoting existing hair growth, or strengthening hair with a condition: robust evidence must exist. [1]

For a private-label team, the operational question is not whether someone has supplied a generic marketing deck or an informal ingredient narrative. The question is whether the brand’s approval file contains supporting material that can be reviewed against the exact proposed wording. This guide does not specify a clinical-study design, consumer-study protocol, test method, ingredient concentration or performance threshold because no verified information on those matters is within its scope.

A proportionate internal checkpoint should record:

the exact claim, including product name, headline, body copy, qualifiers and visual callouts;
the media in which the claim will appear, such as pack, product page, marketplace listing or paid advertisement;
the UK target market;
the location and status of the supporting substantiation package;
the reviewer responsible for the claim decision; and
the final disposition: approved, revised, held or escalated.

This record does not itself prove substantiation. It prevents a common release-control failure: approving wording while the evidence package is incomplete, unavailable to the reviewer, or connected only to a different claim.

5. A Private-Label Pre-Approval Workflow

The following workflow converts the UK claim distinction into a release control that can be used before supplier artwork is signed off or marketing assets go live.

Figure 1. Private-Label Claim Review Before Artwork Release

Collect all proposed wording. Create one claim inventory covering labels, cartons, inserts, product pages, marketplace copy, advertisements and campaign briefs.
Identify the exact consumer-facing claim. Review the finished phrase rather than a shortened internal description such as “hair benefit.”
Screen prevention and cure language. If the wording says that the product can prevent or cure baldness, hair loss or male-pattern baldness, treat it as likely medicinal-claim wording and escalate before release. [1]
Screen reduction, strengthening and existing-growth wording. If the statement concerns reducing or slowing hair loss, strengthening hair, or promoting existing hair growth, move it to the robust-substantiation checkpoint. [1]
Document the substantiation decision. Confirm whether robust supporting material is available for the exact wording proposed. If it is not available for review, retain a hold status rather than approving the claim.
Release controlled copy only. Provide the approved wording to artwork, e-commerce and media owners. Any later copy change restarts the screen.

The workflow is deliberately conservative. It does not decide that a product is medicinal or non-medicinal, and it does not replace review of final materials. It creates a traceable handoff so that commercial deadlines do not bypass claim review.

6. Claim-Screening Handoff for Procurement, Brand and Compliance Teams

Before issuing a packaging purchase order or activating a UK campaign, the project owner should circulate a short handoff sheet. This is especially important when the formula supplier, packaging designer, marketplace agency and brand owner are different organisations.

Table 2. Packaging and Marketing Claim Handoff Checklist

Handoff field	What the approval request should contain	Release-control purpose
Exact proposed wording	Verbatim text for every claim, headline, callout and qualifier.	Prevents approval of an abbreviated claim that differs from the printed or published version.
Intended medium	Pack, carton, product-detail page, marketplace listing, paid advertisement or other UK-facing material.	Ensures all consumer-facing uses are included in the screen.
Target market	United Kingdom.	Prevents UK guidance from being used as a substitute for another jurisdiction’s review.
Screening outcome	Ordinary substantiation review, revision required, or specialist escalation.	Separates potentially non-medicinal wording from language likely to be medicinal. [1]
Supporting-material status	Available for review, incomplete, not available, or not applicable following escalation.	Applies the robust-evidence checkpoint to claims that may be non-medicinal. [1]
Review owner and decision	Named decision owner, decision date and approved final copy version.	Creates a controlled record before print or publication.

Procurement should treat an unresolved claim status as a commercial hold point. A supplier may be ready to print packaging, but production readiness does not resolve claim classification or substantiation. Conversely, a completed wording screen does not validate formula quality, safety, product notification, labelling or other UK obligations that sit outside this guide.

7. UK Scope Limits and When to Obtain Market-Specific Review

This resource is limited to the UK advertising context reflected in the cited guidance. It does not provide legal advice or a medicinal-product classification determination. It also does not assess product efficacy, active ingredients, formula concentrations, stability, microbiological quality, packaging compatibility, clinical evidence, product safety documentation or complete UK cosmetics compliance requirements.

Obtain market-specific review when the product will be offered outside the United Kingdom, when the final claim wording includes prevention or cure of baldness, hair loss or male-pattern baldness, or when the team cannot establish that robust support is available for claims concerning reduced hair loss, stronger hair or promotion of existing hair growth. [1]

The final practical rule is simple: lock every UK-facing hair-loss-related phrase before commercial release. Escalate likely medicinal wording, require robust support for wording that may be non-medicinal, and retain a documented approval record that follows the copy from artwork to advertising.

References

[1] Advertising Standards Authority / Committee of Advertising Practice. Hair: General. UK advertising guidance, updated 16 October 2025. https://www.asa.org.uk/advice-online/hair-care.html. Accessed 3 April 2026.